APA (7th ed.) Citation

Gianluca Furneri, Laura Santoni, Chiara Ricella, & Luca Prosperini. (2019). Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy. BMC.

Chicago Style (17th ed.) Citation

Gianluca Furneri, Laura Santoni, Chiara Ricella, and Luca Prosperini. Cost-effectiveness Analysis of Escalating to Natalizumab or Switching Among Immunomodulators in Relapsing-remitting Multiple Sclerosis in Italy. BMC, 2019.

MLA (9th ed.) Citation

Gianluca Furneri, et al. Cost-effectiveness Analysis of Escalating to Natalizumab or Switching Among Immunomodulators in Relapsing-remitting Multiple Sclerosis in Italy. BMC, 2019.